Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Biocon’s stock jumped on December 24 after the United States Food and Drug Administration (USFDA) and the European Union ...

Shares of the biopharma major rose earlier today when it announced that its European partner, Zentiva, received a procedure ...

Biocon shares had gained earlier in the day after the company and its European partner Zentiva received a decentralised ...

India to become a global leader in development of complex biotherapeutic products: Kiran Mazumdar Shaw: Nandita Vijayasimha, Bengaluru Tuesday, December 31, 2024, 08:00 Hrs [IST] ...

The rise in Biocon share price came after it announced that the company and its European partner, Zentiva, have received a ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

Bengaluru: Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from ...

Biocon and Zentiva gain EU approval for generic Liraglutide, marking milestone in expanding complex generic medication ...

Bangalore: Biocon and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex ...

Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...